timothy sykes logo
KOD Stock Jumps As Phase 3 Retina Catalysts Approach Thumbnail
G Google News

KOD Stock Jumps As Phase 3 Retina Catalysts Approach

ELLIS HOBBS•UPDATED SEP. 28, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Kodiak Sciences Inc soars as pivotal clinical trial success fuels optimism, and stocks have been trading up by 87.2 percent.

Key Takeaways

  • UBS reiterates a Buy on Kodiak Sciences, tying an $80 price target to upcoming Phase 3 wet AMD data for tarcocimab and KSI-501 versus Eylea, well above the roughly $31 share level.
  • Multiple near-term catalysts for KOD include September topline data, an October AAO presentation, and December readouts that traders see as potential fuel after a recent pullback.
  • Goldman Sachs resumes coverage of Kodiak Sciences with a Neutral rating and a $36 target, leaning on a constructive biotech backdrop of M&A, clinical wins, and easier regulation.
  • Kodiak Sciences will present pivotal Phase 3 DAYBREAK topline results on 2026/09/28 for Zenkuda (tarcocimab tedromer) and KSI-501 in wet AMD, spotlighting a late-stage retina pipeline and additional Phase 3 timelines.

Candlestick Chart

Live Update At 09:19:10 EDT: On Monday, September 28, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 87.2%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Kodiak Sciences, ticker KOD, is trading like a classic high-risk, high-reward biotech into major data. The daily chart shows the stock stuck mostly in the low-to-mid $30s over recent sessions, closing around $32–$33 after a pullback from the mid-$30s. That range-bound action hides a wild intraday story.

The 5-minute tape shows KOD spiking from the low $30s in premarket up through the $40s, then ripping as high as the mid-$60s before fading. That is extreme volatility. For active traders, it signals a name where liquidity is building and emotions are running hot ahead of the Phase 3 DAYBREAK readout.

More Breaking News

On the fundamentals, Kodiak Sciences is still a development-stage biotech burning cash. The latest quarterly numbers show about $132.1M of cash at 2026/06/30, down from $175.7M, with free cash flow at roughly -$46.6M for the quarter. KOD posted a net loss of about $65.6M and heavily negative returns on equity, which is normal for a company funding big retina trials. Financial strength ratios show decent breathing room, with a current ratio near 2.5 and meaningful working capital. Translation for traders: the balance sheet buys time, but the real driver is clinical data, not earnings.

Why Traders Are Watching KOD Into Phase 3 Data

Kodiak Sciences is stepping into a make-or-break period, and traders know it. UBS has leaned in on the bullish side, reiterating a Buy on KOD and slapping on an $80 price target while the stock has been trading near $31. That kind of gap gets momentum traders’ attention fast. UBS is not just throwing out a number; the call is tied directly to Phase 3 wet AMD trials for tarcocimab and KSI-501.

The key point from UBS is non-inferiority to Eylea, the entrenched standard in wet AMD, with a shot at extended dosing intervals. In plain English, if Kodiak Sciences can match Eylea on vision outcomes while needing fewer injections, the commercial story for KOD changes overnight. That is why so many are crowding into the trade ahead of the data.

The catalyst calendar is also packed. UBS highlights September topline data, an October presentation at the AAO meeting, and more data in December. Each event is another potential spark for KOD’s chart. Short-term traders love that setup: clear dates, binary reactions, and room for big percentage moves.

At the same time, Goldman Sachs brings a cooler tone. Goldman resumed coverage of Kodiak Sciences with a Neutral rating and a $36 price target, acknowledging broad strength in biotech from M&A and clinical wins but being more cautious on upside for KOD specifically. That split between UBS and Goldman shapes how trading plays out: aggressive players lean on the UBS upside story, while more cautious money respects the Goldman cap closer to current levels.

Layer on the company’s own news that Kodiak Sciences will present pivotal Phase 3 DAYBREAK topline results on 2026/09/28 for Zenkuda and KSI-501 in wet AMD, plus further Phase 3 timelines in other retinal indications, and you have a classic event-driven biotech setup. Volatility is not a bug here. It is the feature.

Conclusion

Kodiak Sciences sits at the crossroads of science, sentiment, and pure trading psychology. The balance sheet shows KOD has enough cash for now but not enough to ignore the burn rate forever. The income statement is deep in the red, as expected for a development-stage biotech. None of that is new. What is new, and what the market is truly trading, is the cluster of Phase 3 data drops coming over the next few months.

For short-term traders, KOD has already flashed its personality: violent premarket spikes from the $30s to the $60s, wide intraday ranges, and strong reactions to every analyst comment. UBS’s $80 target frames the upside if DAYBREAK and the broader retina program deliver. Goldman’s $36 target reminds everyone that Street opinion is not unanimous and that disappointment will hurt.

Kodiak Sciences has laid out a clear path: pivotal DAYBREAK topline results on 2026/09/28, followed by detailed data at AAO in October and further readouts into December. Each date is a decision point for KOD traders. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” As Tim Sykes loves to say, “Volatile catalysts are a gift if you’re prepared and disciplined — but they’re a disaster if you’re lazy and stubborn.” For those tracking Kodiak Sciences, the play is not to predict the science. It is to respect the risk, study the chart, and trade the reaction, not the hope.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”